Latest news with #SNK01
Yahoo
14-04-2025
- Business
- Yahoo
NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition
SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will be speaking at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025), to be held in Beijing, China, April 16-18, 2025. BIOTEC-CHINA 2025 is a premier gathering of biotechnology and pharmaceutical professionals from across the globe. With close to 1,500 attendees, the event offers a unique opportunity for intensive networking, collaboration, and the exploration of promising new partnerships. Covering a broad range of life science research and applications, BIOTEC-CHINA 2025 will spotlight key innovation areas such as drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy. NKGen Presentation Details: Title: Use of Autologous Enhanced Natural Killer Cells for Alzheimer's and Parkinson's Disease Location: Shuijing Hall, Beijing Huanghe Jingdu Conference Center, The Third Building Date and Time: April 17, 2025, at 10:20 am – 10:40 am CST (China Standard Time) UTC/GMT +8 Dr. Song will present on the use of troculeucel in the treatment of patients with Alzheimer's and Parkinson's disease, highlighting the promising results previously observed in our Phase 1 clinical trials and compassionate use cases. Additionally, Dr. Song will provide an update on NKGen's ongoing Phase 1/2a clinical trial for moderate Alzheimer's disease, with recent data presented at the AD/PD™ 2025 conference. The favorable clinical outcomes and biomarker data disclosed to date offer strong indications that troculeucel may emerge as a viable treatment option for patients with Alzheimer's and Parkinson's disease. Previously disclosed data for troculeucel in Alzheimer's disease can be found on the Scientific Publications page of the Company's website at News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company's website at About TroculeucelTroculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market. About NKGen BiotechNKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact:Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@ External Contact:Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@ in to access your portfolio
Yahoo
25-03-2025
- Business
- Yahoo
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)
SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ('AD/PD™ 2025') taking place online and in Vienna, Austria from April 1 – 5, 2025. AD/PD™ 2025 is a premier event bringing together top international experts to discuss the latest advancements in Alzheimer's and Parkinson's research, clinical trials, and treatments. With over 4,700 participants from 70+ countries and 2,250 abstracts in 2024, it offers a platform for groundbreaking discoveries from the leading experts in the field. Presentation Details: Title: Preliminary Cognitive Improvement in Phase 1 Cohort of Moderate Alzheimer's Disease Subjects Treated with Autologous Natural Killer Cells (Troculeucel; SNK01) Session Name: 7540 – Advances in AD Drug Development 02 Session Type: Symposium Presentation Date: Saturday, April 5, 2025, at 5:10 pm – 5:25 pm CEST Room: Hall E Dr. Song's presentation will focus on the three-month cognitive and biomarker results from the Phase 1 cohort of the Phase 1/2a clinical trial for troculeucel NK cell therapy in moderate Alzheimer's disease, as well as new data from the six-month analysis of this cohort. Previously disclosed data for troculeucel in Alzheimer's disease and solid tumors can be found on the Scientific Publications page of the Company's website at News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company's website at About TroculeucelTroculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market. About NKGen BiotechNKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact:Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@ External Contacts:Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@
Yahoo
13-03-2025
- Business
- Yahoo
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit
SANTA ANA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit (the 'Summit') to be held in Boston, MA, from March 18–20, 2025. Dr. Song's presentation will highlight troculeucel, the Company's autologous, non-genetically modified NK cell therapy, as a potential treatment for neurodegenerative diseases. The Summit is the only industry-focused event covering the entire drug development process from discovery to commercialization. This year's Summit will spotlight advancements in neurodegenerative therapeutics, presymptomatic diagnosis, and new targets, modalities, and technologies. Over 150 experts will collaborate to address key challenges and drive the next wave of transformative treatments. Presentation Details: Title: Showcasing the Potential of Enhanced NK Cell Therapies for the Treatment of Neurodegenerative Disease: Introducing Troculeucel Conference Track: In Vivo Translation & Early Clinical Date and Time: March 20, 2025, at 12:00 PM ET Dr. Song's presentation will showcase the potential of enhanced NK cell therapy for the treatment of neurodegenerative disease, introducing troculeucel. Dr. Song will outline the mechanism of troculeucel, the Company's novel, autologous NK cell therapy, for treating neurodegeneration. He will also present promising data from the Company's Phase 1 clinical trial, demonstrating early signs of clinical benefit, leading to the U.S. Food and Drug Administration Fast Track designation for moderate Alzheimer's Disease and a new Investigational New Drug for Parkinson's Disease. Moreover, Dr. Song will highlight the future directions for troculeucel in Frontotemporal Dementia and post-stroke/traumatic brain injury. Previously disclosed data for troculeucel in Alzheimer's disease and solid tumors can be found on the Scientific Publications page of the Company's website at News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company's website at About TroculeucelTroculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market. About NKGen BiotechNKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit Forward-Looking StatementsStatements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact:Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@ External Contacts:Chris CalabreseManaging DirectorLifeSci Advisors, LLCccalabrese@ Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@ in to access your portfolio
